Gabriel Hortobagyi

986 total citations
18 papers, 690 citations indexed

About

Gabriel Hortobagyi is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Gabriel Hortobagyi has authored 18 papers receiving a total of 690 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 5 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Cancer Research. Recurrent topics in Gabriel Hortobagyi's work include Bone health and treatments (5 papers), HER2/EGFR in Cancer Research (5 papers) and Breast Cancer Treatment Studies (4 papers). Gabriel Hortobagyi is often cited by papers focused on Bone health and treatments (5 papers), HER2/EGFR in Cancer Research (5 papers) and Breast Cancer Treatment Studies (4 papers). Gabriel Hortobagyi collaborates with scholars based in United States, United Kingdom and France. Gabriel Hortobagyi's co-authors include Parul Patel, David Chen, Mary Ellen Moynahan, Sarat Chandarlapaty, Patricia Sung, Aliaksandra Samoila, Wei He, José Baselga, Michael Gnant and Daoqi You and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Gabriel Hortobagyi

18 papers receiving 665 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gabriel Hortobagyi United States 9 437 274 265 199 142 18 690
D. Ilegbodu United States 12 574 1.3× 181 0.7× 162 0.6× 105 0.5× 79 0.6× 30 711
Rolando Nortilli Italy 18 611 1.4× 115 0.4× 266 1.0× 190 1.0× 81 0.6× 36 808
Janice F. Eakle United States 9 565 1.3× 345 1.3× 265 1.0× 246 1.2× 78 0.5× 22 805
Zafeiris Zafeiriou United Kingdom 13 422 1.0× 536 2.0× 345 1.3× 158 0.8× 38 0.3× 31 873
C. Hudis United States 13 632 1.4× 100 0.4× 204 0.8× 214 1.1× 30 0.2× 59 801
В. С. Медведев Russia 4 397 0.9× 242 0.9× 103 0.4× 207 1.0× 118 0.8× 11 950
Theresa Link Germany 13 501 1.1× 184 0.7× 310 1.2× 190 1.0× 38 0.3× 55 754
T Yoshikubo Japan 9 453 1.0× 156 0.6× 174 0.7× 168 0.8× 37 0.3× 16 765
Abigail Evans United Kingdom 13 414 0.9× 186 0.7× 279 1.1× 161 0.8× 84 0.6× 32 661
Hielke J. Meulenbeld Netherlands 11 283 0.6× 316 1.2× 176 0.7× 149 0.7× 26 0.2× 17 577

Countries citing papers authored by Gabriel Hortobagyi

Since Specialization
Citations

This map shows the geographic impact of Gabriel Hortobagyi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel Hortobagyi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel Hortobagyi more than expected).

Fields of papers citing papers by Gabriel Hortobagyi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriel Hortobagyi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel Hortobagyi. The network helps show where Gabriel Hortobagyi may publish in the future.

Co-authorship network of co-authors of Gabriel Hortobagyi

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriel Hortobagyi. A scholar is included among the top collaborators of Gabriel Hortobagyi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriel Hortobagyi. Gabriel Hortobagyi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Bárcenas, Carlos H., Akshara Singareeka Raghavendra, A. K. Sinha, et al.. (2017). Outcomes in patients with early‐stage breast cancer who underwent a 21‐gene expression assay. Cancer. 123(13). 2422–2431. 19 indexed citations
2.
Chandarlapaty, Sarat, David Chen, Wei He, et al.. (2016). Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer. JAMA Oncology. 2(10). 1310–1310. 347 indexed citations
3.
Zhang, Siyuan, Wen‐Chien Huang, Ping Li, et al.. (2011). Abstract LB-379: Combating trastuzumab resistance by targeting Src, a common node downstream of multiple resistance pathways. Cancer Research. 71(8_Supplement). LB–379. 2 indexed citations
4.
Cristofanilli, Massimo, et al.. (2005). In Reply:. Journal of Clinical Oncology. 23(27). 6796–6797. 1 indexed citations
5.
Rivera, Edgardo, Debbie Frye, Nuhad K. Ibrahim, et al.. (2005). Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 57(4). 540–544. 4 indexed citations
6.
Morandi, Paolo, Roman Rouzier, Kadri Altundağ, et al.. (2004). The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma. Cancer. 101(7). 1482–1489. 26 indexed citations
7.
Hortobagyi, Gabriel. (2003). Novel approaches to the management of bone metastases. Seminars in Oncology. 30(5 Suppl 16). 161–166. 9 indexed citations
8.
Nahta, Rita, Gabriel Hortobagyi, & Francisco J. Esteva. (2003). Signal Transduction Inhibitors in the Treatment of Breast Cancer. PubMed. 3(3). 201–216. 4 indexed citations
9.
Hortobagyi, Gabriel. (2001). Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Seminars in Oncology. 28(6 Suppl 18). 43–47. 82 indexed citations
10.
Hortobagyi, Gabriel. (2001). Unmet needs in metastatic bone disease and its complications: Is progress possible?. Seminars in Oncology. 28(2 Suppl 6). 1–3. 6 indexed citations
11.
Gale, Robert Peter, Rolla Edward Park, Robert W. Dubois, et al.. (2000). Delphi‐panel analysis of appropriateness of high‐dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clinical Transplantation. 14(1). 32–41. 13 indexed citations
12.
Major, Pierre, Allan Lipton, James R. Berenson, & Gabriel Hortobagyi. (2000). Oral bisphosphonates. Cancer. 88(1). 6–14. 1 indexed citations
13.
Lipton, Allan, L. Demers, Vernon M. Chinchilli, et al.. (1998). Markers of bone resorption in patients treated with pamidronate. European Journal of Cancer. 34(13). 2021–2026. 126 indexed citations
14.
Bonadonna, Gianni, Gabriel Hortobagyi, & Pinuccia Valagussa. (1997). Textbook of Breast Cancer: A Clinical Guide to Therapy. Medical Entomology and Zoology. 28 indexed citations
15.
Lipton, Allan, Laurence M. Demers, L. Gaydos, et al.. (1995). Markers of bone resorption in patients treated with pamidronate. Bone. 17(6). 615–615. 3 indexed citations
16.
Voravud, Narin, Meletios Α. Dimopoulos, Gabriel Hortobagyi, Merrick I. Ross, & Richard L. Theriault. (1991). Breast cancer and second primary ovarian cancer in dermatomyositis. Gynecologic Oncology. 43(3). 286–290. 11 indexed citations
17.
Lee, Jin S., Vicki L. Hopwood, Barbara Tomasovic, et al.. (1987). 53 A cytogenetic study of human primary breast tumor and nonmaligant breast tissue. Cancer Genetics and Cytogenetics. 28(1). 42–42. 1 indexed citations
18.
Tannir, Nizar M., H. Y. Yap, Gabriel Hortobagyi, et al.. (1984). Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone.. PubMed. 68(7-8). 1039–41. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Ilegbodu Breakdown of academic impact, for papers by Rolando Nortilli Breakdown of academic impact, for papers by Janice F. Eakle Breakdown of academic impact, for papers by Zafeiris Zafeiriou Breakdown of academic impact, for papers by C. Hudis Breakdown of academic impact, for papers by В. С. Медведев Breakdown of academic impact, for papers by Theresa Link Breakdown of academic impact, for papers by T Yoshikubo Breakdown of academic impact, for papers by Abigail Evans Breakdown of academic impact, for papers by Hielke J. Meulenbeld
Rankless by CCL
2026